Primary pulmonary lymphoepithelioma-like carcinoma

Fifty-two patients with long-term follow-up

Authors

  • Ying Liang MD,

    1. Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    2. State Key Laboratory of Oncology in South China/Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    Search for more papers by this author
    • The first 3 authors contributed equally to this article.

  • Liang Wang MD,

    1. State Key Laboratory of Oncology in South China/Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    2. Department of Hematologic Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    Search for more papers by this author
    • The first 3 authors contributed equally to this article.

  • Yujia Zhu MD,

    1. State Key Laboratory of Oncology in South China/Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    2. Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    Search for more papers by this author
    • The first 3 authors contributed equally to this article.

  • Yongbin Lin MD, PhD,

    Corresponding author
    1. State Key Laboratory of Oncology in South China/Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    2. Department of Thoracic Surgery, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    • Department of Thoracic Surgery, State Key Laboratory of Oncology in South China/Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, P.R. China
    Search for more papers by this author
    • Fax: (011) 0086-020-87343694

  • Hui Liu MD,

    1. State Key Laboratory of Oncology in South China/Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    2. Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    Search for more papers by this author
  • Huilan Rao MD,

    1. State Key Laboratory of Oncology in South China/Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    2. Department of Pathology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    Search for more papers by this author
  • Guangchuan Xu MD,

    1. Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    2. State Key Laboratory of Oncology in South China/Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    Search for more papers by this author
  • Tiehua Rong MD

    1. State Key Laboratory of Oncology in South China/Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    2. Department of Thoracic Surgery, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    Search for more papers by this author

Abstract

BACKGROUND:

Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare kind of cancer.

METHODS:

In this study, the authors evaluated 52 patients with pulmonary LELC who had long-term follow-up. Clinical characteristics, tumor markers, epidermal growth factor receptor (EGFR) mutation status, treatments, and outcomes were analyzed.

RESULTS:

Pulmonary LELC mostly affected young, nonsmoking patients. Most patients were in early or locally advanced stages and received multimodality treatment. Serum levels of neuron-specific enolase and cytokeratin 19 fragment 21-1 were elevated in 11 of 20 patients and 10 of 16 patients, respectively. Mutational analysis of EGFR was done in 11 patients, and all were wild type. The median overall survival (OS) for all the patients was not reached, and the 2-year and 5-year OS rate was 88% and 62%, respectively. The patients with early tumor stage, normal serum lactate dehydrogenase level, normal serum albumin level, without lymph node metastasis, and those who underwent complete resection had significantly better OS (P < .05); and the serum albumin level was an independent prognostic factor in a Cox regression model (P = .005). For all patients who underwent complete resection, whether or not they received adjuvant chemotherapy did not affect OS (P > .05); whereas, for patients with stage IIIA disease who underwent complete resection, adjuvant chemotherapy was correlated with a significantly better prognosis (P < .05).

CONCLUSIONS:

Pulmonary LELC obviously is a distinct entity of lung cancer that has a better prognosis, because patients with LELC can receive multimodality treatment, and LELC has biologic behavior similar to that of nasopharyngeal carcinoma. The current results indicated that future collaborative efforts are needed to determine the optimal treatment methods for this uncommon malignancy. Cancer 2012. © 2012 American Cancer Society.

Ancillary